JB Chemicals & Pharmaceuticals (JBCPL), is one of India's leading pharmaceutical companies, announced its foray into the area of Nephrology with a new dedicated division called "RENOVA" which will endeavour to serve patients who are under treatment for Chronic Kidney Disease.

The new division will focus exclusively on comprehensive renal care ranging from the management of hypertension in Chronic Kidney Disease (CKD) to End-stage renal disease. After successfully becoming one of the leading player in Hypertension with brands like Cilacar and Nicardia , JBCPL has now begun to also focus on patients with CKD.

"Being one of leaders in the hypertension segment, we realised that Chronic Kidney Disease is a major issue in the country and the numbers are rising significantly. There are growing cases of hypertension associated with CKD and we believe this initiative will enable us service the growing unmet needs of CKD patients," Nikhil Chopra, CEO & Whole time director, J.B. Chemicals & Pharmaceuticals said.

Shares of the company gained Rs 12.4, or 0.85%, to settle  at  Rs 1,465.80.  The total volume of shares traded  was  4,148 at  the BSE (Friday).